http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0331213-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af737d167c026fd865fb68df681ea49a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
filingDate 1990-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a33b4edbf78c9d1a730b445851cf072c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bca42dea5d55732ba29f7e67b79974f
publicationDate 1991-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H0331213-A
titleOfInvention Treatment of postmenopausal disorder
abstract PURPOSE: To treat postmenopausal disorder without causing endomentrial hyperplasia by continuously administering an estrogen compound and progestogen compound by a specific method. n CONSTITUTION: A natural or synthetic estrogen compound (preferably estradiol valerate) effective in preventing postmenopausal disorder is orally administered in a daily dose of 2mg without interrupting for 69 days and the estrogen compound and a compound having progesterone activity effective in preventing the development of endomentrial hyperlasia (preferably medroxyprogesterone acetate) are continuously administered each in daily doses of 2mg and 20mg from the 70th day to the 83rd following first day and a compound free of estrogen and progestogen is continuously daily administered without interrupting from the 84th day to the 90th following first day of a compound free of estrogen and progestogen. n COPYRIGHT: (C)1991,JPO
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0526769-A
priorityDate 1989-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396304
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5994
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66586975
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425793
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535674
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13791
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134688829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553937
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399016
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14653378
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18609376
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6279
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425794

Total number of triples: 36.